Home > Riviste > Minerva Stomatologica > Fascicoli precedenti > Articles online first > Minerva Stomatologica 2014 Jan 14





Rivista di Odontostomatologia e Chirurgia Maxillo-Facciale

Official Journal of the Italian Society of Odontostomatology and Maxillofacial Surgery
Indexed/Abstracted in: CAB, EMBASE, Index to Dental Literature, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index



Minerva Stomatologica 2014 Jan 14


lingua: Inglese

Blood levels of interleukins in patients with ameloblastoma

Corega C. 1, 2, Vaida L. 3, Festila D. G. 4, Rigoni G. 5, Albanese M. 5, D’agostino A. 5, Pardo A. 5, Marconcini S. 6, Gelpi F. 7, Nocini P. F. 5, Bertossi D. 5

1 Department of Orthodontics, University Paris V Renee Descartes, Paris, France; 2 University of Medicine and Pharmacy, Iuliu Hatieganu, Cluj-Napoca, Romania; 3 Department of Dental Medicine, Faculty of Medicine and Pharmacy University of Oradea, Oradea, Romania; 4 Department of Orthodontics, University of Medicine and Pharmacy, “Iuliu Hatieganu”, Cluj-Napoca, Romania; 5 Section of Dentistry and Maxillofacial Surgery, Department of Surgery, University of Verona, Verona, Italy; 6 Assistant Professor, Istituto Stomatologico Toscano, Versilia General Hospital, Italy; 7 Centro Odontostomatologico, Ospedale Sacro Cuore, Don Calabria, Verona, Italy


The aim of study was to determine and compare serum concentrations of interleukin 1 beta (IL-1β), interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α) in patients with oral ameloblastoma and healthy controls. Sixteen patients with ameloblastoma and 16 healthy controls were enrolled in this study. Cytokine concentrations were measured by chemiluminescent enzyme linked immunoassay. Serum concentrations of IL-1β were below level of detection in all but four participants. No significant differences between the groups were observed in serum concentrations of IL-6. Serum TNF-α was significantly higher in control subjects than in ameloblastoma patients. Patients diagnosed with ameloblastoma have relatively normal levels of inflammatory cytokines in their blood and thus cannot be used as indicators of disease severity or for monitoring the treatment outcomes.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail